

Denne protokollen er utferdiget både på norsk og på engelsk. Ved uoverensstemmelser mellom de to versjonene, skal den norske versjonen gå foran.

These minutes have been prepared both in Norwegian and in English. In case of discrepancies between the two versions, the Norwegian version shall prevail.

**PROTOKOLL FRA ORDINÆR  
GENERALFORSAMLING I NYKODE  
THERAPEUTICS ASA**

**MINUTES OF THE ANNUAL GENERAL MEETING  
IN NYKODE THERAPEUTICS ASA**

Ordinær generalforsamling i Nykode Therapeutics ASA ("**Selskapet**") ble avholdt på møterom FORUM - Bygg H, Plan 0 i Gaustadalléen 21, Oslo, den 13. mai 2026 kl. 10.00.

The Annual General Meeting of Nykode Therapeutics ASA (the "**Company**") was held at meeting room FORUM - Building H, Plan 0 in Gaustadalléen 21, Oslo, Norway at 10.00 CEST on May 13, 2026.

En liste over fremmøtte aksjonærer og fullmakter er inntatt som Vedlegg 1 til denne protokollen. Av vedlegget fremgår også antall aksjer og prosentandel av Selskapets aksjekapital som var representert på generalforsamlingen.

A list of shareholders in attendance and proxies is included as Appendix 1 to these minutes. The appendix also states the number of shares and the percentage of the Company's share capital that were represented at the General Meeting.

Følgende saker forelå på agendaen:

The following items were on the agenda:

**1. VALG AV MØTELEDER OG ÉN PERSON  
TIL Å MEDSIGNERE PROTOKOLLEN**

**1. ELECTION OF CHAIR OF THE MEETING  
AND ONE PERSON TO CO-SIGN THE  
MINUTES**

Audun Bondkall ble valgt som møteleder, og Harald Gurvin ble valgt til å medundertegne protokollen sammen med møteleder.

Audun Bondkall was appointed as chair of the meeting, and Harald Gurvin was elected to co-sign the minutes with the chair.

**2. GODKJENNELSE AV INNKALLING OG  
DAGSORDEN**

**2. APPROVAL OF NOTICE AND AGENDA**

Innkalling og dagsorden for møtet ble godkjent.

The notice and the agenda for the meeting were approved.

**3. GODKJENNELSE AV ÅRSREGNSKAP OG  
ÅRSBERETNING FOR REGNSKAPSÅRET  
2025**

**3. APPROVAL OF ANNUAL ACCOUNTS AND  
ANNUAL REPORT FOR THE FINANCIAL  
YEAR 2025**

I samsvar med styrets forslag, fattet generalforsamlingen følgende vedtak:

In accordance with the proposal from the Board of Directors, the General Meeting passed the following resolution:

*"Selskapets årsregnskap og årsberetning for regnskapsåret 2025 godkjennes."*

*"The Company's annual accounts and annual report for the financial year 2025 are approved."*

**4. VURDERING AV STYRETS  
RETNINGSLINJER OM FASTSETTELSE AV  
LØNN OG ANNEN GODTGJØRELSE TIL  
LEDENDE PERSONER**

I samsvar med styrets forslag, fattet i generalforsamlingen følgende vedtak:

*"Generalforsamlingen godkjente retningslinjene for fastsettelse av lønn og annen godtgjørelse til ledende personer, som foreslått av styret."*

**4. CONSIDERATION OF THE BOARD OF  
DIRECTORS' GUIDELINES REGARDING  
STIPULATION OF SALARY AND OTHER  
REMUNERATION TO THE EXECUTIVE  
PERSONS**

In accordance with the proposal from the Board of Directors, the General Meeting passed the following resolution:

*"The general meeting approved the guidelines for determining remuneration to the executive persons, as proposed by the board of directors."*

**5. VURDERING AV STYRETS RAPPORT OM  
LØNN OG ANNEN GODTGJØRELSE TIL  
LEDENDE PERSONER**

I samsvar med styrets forslag, fattet i generalforsamlingen følgende vedtak:

*"Generalforsamlingen godkjente rapport om lønn og annen godtgjørelse til ledende personer, som foreslått av styret."*

**5. CONSIDERATION OF THE BOARD OF  
DIRECTORS' REPORT ON SALARY AND  
OTHER REMUNERATION TO THE  
EXECUTIVE PERSONS**

In accordance with the proposal from the Board of Directors, the General Meeting passed the following resolution:

*"The general meeting approved the report on salary and other remuneration to the executive persons, as proposed by the board of directors."*

**6. BEHANDLING AV STYRETS ERKLÆRING  
OM EIERSTYRING OG  
SELSKAPSLEDELSE**

Generalforsamlingen tok til etterretning styrets erklæring om eierstyring og selskapsledelse.

**6. CONSIDERATION OF THE BOARD OF  
DIRECTORS' STATEMENT ON  
CORPORATE GOVERNANCE**

The General Meeting took note of the Board of Directors' statement on corporate governance.

**7. HONORAR TIL REVISOR**

I samsvar med styrets forslag, fattet i generalforsamlingen følgende vedtak:

*"Honorar til revisor for 2025 slik det fremgår av årsregnskapet for 2025 godkjennes."*

**7. FEES TO THE AUDITOR**

In accordance with the proposal from the Board of Directors, the General Meeting passed the following resolution:

*"The fees to the auditor for 2025 as set out in the annual accounts for 2025 are approved."*

**8. VALG AV STYRE**

I samsvar med valgkomitéens forslag, fattet generalforsamlingen følgende vedtak:

*"Christian Åbyholm gjenvelges som medlem av styret."*

De resterende styremedlemmene er ikke på valg og fortsetter sine verv.

Styret vil etter dette fortsette å bestå av:

Barbara Krebs-Pohl (styrets leder)  
John Beadle  
Susanne Stuffers  
Christian Åbyholm  
Trygve Lauvdal

**9. HONORAR TIL STYRET**

I samsvar med valgkomitéens forslag, fattet generalforsamlingen følgende vedtak:

*"Generalforsamlingen godkjenner følgende honorarer til styret for perioden fra ordinær generalforsamling i 2026 og frem til ordinær generalforsamlingen i 2027:*

*Barbara Krebs-Pohl (styrets leder) – EUR 50 000  
John Beadle – EUR 30 000  
Susanne Stuffers– NOK 350 000  
Christian Åbyholm – NOK 250 000  
Trygve Lauvdal – NOK 250 000*

*Revisjonsutvalget:*

*Leder – NOK 60 000  
Medlem – NOK 30 000*

**8. ELECTION OF THE BOARD OF DIRECTORS**

In accordance with the proposal from the Nomination Committee, the General Meeting passed the following resolution:

*"Christian Åbyholm is re-elected as member of the Board."*

The remaining board members are not up for election, and will continue their directorships.

Following this, the Board of Directors will continue to consist of:

Barbara Krebs-Pohl (Chair of the Board)  
John Beadle  
Susanne Stuffers  
Christian Åbyholm  
Trygve Lauvdal

**9. REMUNERATION TO THE BOARD OF DIRECTORS**

In accordance with the proposal from the Nomination Committee, the General Meeting passed the following resolution:

*"The General Meeting approves the following remuneration to the Board for the period from the Annual General Meeting in 2026 until the Annual General Meeting in 2027:*

*Barbara Krebs-Pohl (Chair of the Board) – EUR 50,000  
John Beadle – EUR 30,000  
Susanne Stuffers– NOK 350,000  
Christian Åbyholm – NOK 250,000  
Trygve Lauvdal – NOK 250,000*

*Audit Committee:*

*Chair – NOK 60,000  
Member – NOK 30,000*

Forsknings- og utviklingsutvalget:

Leder – NOK 90 000  
Medlem – NOK 45 000"

Research and Development Committee:

Chair – NOK 90,000  
Member – NOK 45,000"

#### 10. VALG AV VALGKOMITÉ

I samsvar med valgkomitéens forslag, fattet generalforsamlingen følgende vedtak:

*"Lars Erik Larsson og Jan Fikkan gjenvelges som medlemmer av valgkomitéen."*

Komitéens leder, Tom Pike, er ikke på valg og fortsetter i rollen som komitéens leder.

Valgkomitéen vil etter dette fortsette å bestå av:

Tom Pike, komitéens leder  
Lars Erik Larsson  
Jan Fikkan

#### 11. HONORAR TIL VALGKOMITÉEN

I samsvar med valgkomitéens forslag, fattet generalforsamlingen følgende vedtak:

*"Generalforsamlingen godkjenner følgende honorarer til valgkomitéen for perioden fra ordinær generalforsamling i 2026 og frem til ordinær generalforsamling i 2027:*

- Leder: NOK 70 000
- Øvrige medlemmer: NOK 40 000"

#### 10. ELECTION OF THE NOMINATION COMMITTEE

In accordance with the proposal from the Nomination Committee, the General Meeting passed the following resolution:

*"Lars Erik Larsson and Jan Fikkan are re-elected as members of the Nomination Committee."*

The Chair of the Committee, Tom Pike, is not up for election and will continue in his role as Chair of the Committee.

Following this, the Nomination Committee will continue to consist of:

Tom Pike, Chair of the Committee  
Lars Erik Larsson  
Jan Fikkan

#### 11. REMUNERATION TO THE NOMINATION COMMITTEE

In accordance with the proposal from the Nomination Committee, the General Meeting passed the following resolution:

*"The General Meeting approves the following remuneration to the Nomination Committee for the period from the Annual General Meeting in 2026 until the Annual General Meeting in 2027:*

- Chair: NOK 70,000
- Other members: NOK 40,000"

**12. STYREFULLMAKT TIL Å UTSTEDE AKSJER**

I samsvar med styrets forslag, fattet i generalforsamlingen følgende vedtak:

*"Styret gis fullmakt til å øke aksjekapitalen med et maksimumsbeløp på NOK 653 092,89 gjennom én eller flere aksjekapitalutvidelser ved utstedelse av nye aksjer.*

*Tegningskurs per aksje fastsettes av styret i forbindelse med hver enkelt utstedelse.*

*Fullmakten gjelder frem til ordinær generalforsamling i 2027, dog ikke lenger enn til 30. juni 2027.*

*Eksisterende aksjonærers fortrinnsrett til å tegne og bli tildelt aksjer kan fravikes.*

*Fullmakten kan benyttes i forbindelse med (i) kapitalinnhenting til finansiering av selskapets virksomhet; (ii) i forbindelse med oppkjøp og fusjoner, eller (iii) for å oppnå økt spredning av eierskapet i aksjene.*

*Fullmakten omfatter kapitalforhøyelser mot innskudd i kontanter, så vel som kapitalforhøyelser mot innskudd i annet enn kontanter og med særlige tegningsvilkår, jf. allmennaksjeloven § 10-2. Fullmakten omfatter også utstedelse av vederlagsaksjer ved fusjon.*

*Styret vedtar de nødvendige endringer i vedtektene i overensstemmelse med kapitalforhøyelser i henhold til fullmakten."*

**12. BOARD AUTHORISATION TO ISSUE SHARES**

In accordance with the proposal from the Board of Directors, the General Meeting passed the following resolution:

*"The Board is granted the authorisation to increase the share capital by a maximum amount of NOK 653,092.89 in one or more share capital increases through issuance of new shares.*

*The subscription price per share shall be fixed by the Board in connection with each issuance.*

*The authorisation is valid until the Annual General Meeting in 2027, however no longer than until 30 June 2027.*

*Existing shareholders' pre-emptive rights to subscribe for and to be allocated shares may be derogated from.*

*This authorisation may be used in connection with (i) capital raisings for the financing of the company's business; (ii) in connection with acquisitions and mergers, or (iii) to increase the spread of ownership in the shares.*

*The authorisation covers share capital increases against contribution in cash, as well as share capital increases against contribution in kind and with special subscription terms, cf. section 10-2 of the Norwegian Public Limited Liability Companies Act. The authorization also covers issuance of consideration shares in a merger.*

*The Board shall resolve the necessary amendments to the articles of association in accordance with capital increases resolved pursuant to this authorisation."*

**13. STYREFULLMAKT TIL Å UTSTEDE  
AKSJER I FORBINDELSE MED  
INCENTIVPROGRAMMER**

I samsvar med styrets forslag, fattet i generalforsamlingen følgende vedtak:

*"Styret gis fullmakt til å øke aksjekapitalen med et maksimumsbeløp på NOK 32 800 gjennom én eller flere aksjekapitalutvidelser ved utstedelse av nye aksjer.*

*Tegningskurs per aksje fastsettes av styret i forbindelse med hver enkelt utstedelse.*

*Fullmakten gjelder frem til ordinær generalforsamling i 2027, dog ikke lenger enn til 30. juni 2027.*

*Eksisterende aksjonærers fortrinnsrett til å tegne og bli tildelt aksjer kan fravikes.*

*Fullmakten kan kun benyttes i forbindelse med utstedelse av aksjer til ansatte og styremedlemmer i forbindelse med opsjons- og incentivprogrammer, både individuelle og generelle.*

*Styret vedtar de nødvendige endringer i vedtektene i overensstemmelse med kapitalforhøyelser i henhold til fullmakten."*

**13. BOARD AUTHORISATION TO ISSUE  
SHARES IN CONNECTION WITH  
INCENTIVE PROGRAMS**

In accordance with the proposal from the Board of Directors, the General Meeting passed the following resolution:

*"The Board is granted the authorisation to increase the share capital by a maximum amount of NOK 32,800 in one or more share capital increases through issuance of new shares.*

*The subscription price per share shall be fixed by the Board in connection with each issuance.*

*The authorisation is valid until the Annual General Meeting in 2027, however no longer than until 30 June 2027.*

*Existing shareholders' pre-emptive rights to subscribe for and to be allocated shares may be derogated from.*

*This authorisation may only be used in connection with issuance of shares to the employees and board members in relation with option and incentive programs, both individual and general.*

*The Board shall resolve the necessary amendments to the articles of association in accordance with capital increases resolved pursuant to this authorisation."*

---

---

Oslo

13. mai 2026 / 13 May 2026

---

Audun Bondkall (sign)  
Møteleder  
Chair of the meeting

---

Harald Gurvin (sign)  
Medundertegner  
Co-signatory

## Total Represented

ISIN: [NO0010714785 Nykode Therapeutics ASA](#)

General meeting date: 13/05/2026 10.00

Today: 13.05.2026

**Number of persons with voting rights represented/attended : 1**

|   | Number of shares   | % sc           |
|---|--------------------|----------------|
| Total shares                                | 326,546,444        |                |
| - own shares of the company                 | 0                  |                |
| Total shares with voting rights             | 326,546,444        |                |
| Represented by advance vote                 | 95,652,030         | 29.29 %        |
| <b>Sum own shares</b>                       | <b>95,652,030</b>  | <b>29.29 %</b> |
| Represented by proxy                        | 210,700            | 0.07 %         |
| Represented by voting instruction           | 36,190,750         | 11.08 %        |
| <b>Sum proxy shares</b>                     | <b>36,401,450</b>  | <b>11.15 %</b> |
| <b>Total represented with voting rights</b> | <b>132,053,480</b> | <b>40.44 %</b> |
| <b>Total represented by share capital</b>   | <b>132,053,480</b> | <b>40.44 %</b> |

Registrar for the company:

NORDEA BANK ABP, FILIAL NORGE

Signature company:

Nykode Therapeutics ASA

Attendance List Attendance Nykode Therapeutics ASA 13/05/2026

| Ref no  | First Name | Company/Last name                   | Repr. by | Participant     | Share   | Own        | Proxy   | Proxy votes | Total      | % sc    | % registered | % represented | Voting instruction |
|---------|------------|-------------------------------------|----------|-----------------|---------|------------|---------|-------------|------------|---------|--------------|---------------|--------------------|
|         |            |                                     |          |                 | Ordinær | 95,652,030 | 0       | 0           | 95,652,030 | 29.29 % | 72.43 %      | 72.43 %       |                    |
| 1491372 |            | The Chair of the Board of Directors |          | Proxy Solicitor | Ordinær | 0          | 210,700 | 36,190,750  | 36,401,450 | 11.15 % | 27.57 %      | 27.57 %       | FFFFFFFF<br>FF     |

# Protocol for general meeting Nykode Therapeutics ASA

ISIN: [NO0010714785 Nykode Therapeutics ASA](#)

General meeting date: 13/05/2026 10.00

Today: 13.05.2026

| Shares class   | For                | Against          | Poll in            | Abstain      | Poll not registered | Represented shares with voting rights |
|--|--------------------|------------------|--------------------|--------------|---------------------|---------------------------------------|
| <b>Agenda item 1 Election of chair of the meeting and one person to co-sign the minutes</b>  |                    |                  |                    |              |                     |                                       |
| Ordinær  | 132,052,380        | 0                | 132,052,380        | 1,100        | 0                   | 132,053,480                           |
| votes cast in %  | 100.00 %           | 0.00 %           |                    | 0.00 %       |                     |                                       |
| representation of sc in %  | 100.00 %           | 0.00 %           | 100.00 %           | 0.00 %       | 0.00 %              |                                       |
| total sc in %  | 40.44 %            | 0.00 %           | 40.44 %            | 0.00 %       | 0.00 %              |                                       |
| <b>Total</b>   | <b>132,052,380</b> | <b>0</b>         | <b>132,052,380</b> | <b>1,100</b> | <b>0</b>            | <b>132,053,480</b>                    |
| <b>Agenda item 2 Approval of notice and agenda</b>   |                    |                  |                    |              |                     |                                       |
| Ordinær  | 132,048,480        | 5,000            | 132,053,480        | 0            | 0                   | 132,053,480                           |
| votes cast in %  | 100.00 %           | 0.00 %           |                    | 0.00 %       |                     |                                       |
| representation of sc in %  | 100.00 %           | 0.00 %           | 100.00 %           | 0.00 %       | 0.00 %              |                                       |
| total sc in %  | 40.44 %            | 0.00 %           | 40.44 %            | 0.00 %       | 0.00 %              |                                       |
| <b>Total</b>   | <b>132,048,480</b> | <b>5,000</b>     | <b>132,053,480</b> | <b>0</b>     | <b>0</b>            | <b>132,053,480</b>                    |
| <b>Agenda item 3 Approval of annual accounts and annual report for the financial year 2025</b>   |                    |                  |                    |              |                     |                                       |
| Ordinær  | 132,048,480        | 5,000            | 132,053,480        | 0            | 0                   | 132,053,480                           |
| votes cast in %  | 100.00 %           | 0.00 %           |                    | 0.00 %       |                     |                                       |
| representation of sc in %  | 100.00 %           | 0.00 %           | 100.00 %           | 0.00 %       | 0.00 %              |                                       |
| total sc in %  | 40.44 %            | 0.00 %           | 40.44 %            | 0.00 %       | 0.00 %              |                                       |
| <b>Total</b>   | <b>132,048,480</b> | <b>5,000</b>     | <b>132,053,480</b> | <b>0</b>     | <b>0</b>            | <b>132,053,480</b>                    |
| <b>Agenda item 4 Consideration of the Board of Directors' guidelines regarding stipulation of salary and other remuneration to the executive persons</b> |                    |                  |                    |              |                     |                                       |
| Ordinær  | 126,148,110        | 5,901,189        | 132,049,299        | 4,181        | 0                   | 132,053,480                           |
| votes cast in %  | 95.53 %            | 4.47 %           |                    | 0.00 %       |                     |                                       |
| representation of sc in %  | 95.53 %            | 4.47 %           | 100.00 %           | 0.00 %       | 0.00 %              |                                       |
| total sc in %  | 38.63 %            | 1.81 %           | 40.44 %            | 0.00 %       | 0.00 %              |                                       |
| <b>Total</b>   | <b>126,148,110</b> | <b>5,901,189</b> | <b>132,049,299</b> | <b>4,181</b> | <b>0</b>            | <b>132,053,480</b>                    |

| Shares class  | For                | Against          | Poll in            | Abstain      | Poll not registered | Represented shares with voting rights |
|---|--------------------|------------------|--------------------|--------------|---------------------|---------------------------------------|
| <b>Agenda item 5 Consideration of the Board of Directors report on salary and other remuneration to the executive persons</b> |                    |                  |                    |              |                     |                                       |
| Ordinær   | 126,148,110        | 5,901,189        | 132,049,299        | 4,181        | 0                   | 132,053,480                           |
| votes cast in %   | 95.53 %            | 4.47 %           | 0.00 %             |              |                     |                                       |
| representation of sc in %   | 95.53 %            | 4.47 %           | 100.00 %           | 0.00 %       | 0.00 %              |                                       |
| total sc in %   | 38.63 %            | 1.81 %           | 40.44 %            | 0.00 %       | 0.00 %              |                                       |
| <b>Total</b>  | <b>126,148,110</b> | <b>5,901,189</b> | <b>132,049,299</b> | <b>4,181</b> | <b>0</b>            | <b>132,053,480</b>                    |
| <b>Agenda item 7 Fees to the auditor</b>  |                    |                  |                    |              |                     |                                       |
| Ordinær   | 132,025,461        | 23,838           | 132,049,299        | 4,181        | 0                   | 132,053,480                           |
| votes cast in %   | 99.98 %            | 0.02 %           | 0.00 %             |              |                     |                                       |
| representation of sc in %   | 99.98 %            | 0.02 %           | 100.00 %           | 0.00 %       | 0.00 %              |                                       |
| total sc in %   | 40.43 %            | 0.01 %           | 40.44 %            | 0.00 %       | 0.00 %              |                                       |
| <b>Total</b>  | <b>132,025,461</b> | <b>23,838</b>    | <b>132,049,299</b> | <b>4,181</b> | <b>0</b>            | <b>132,053,480</b>                    |
| <b>Agenda item 8.1 Election of the Board of Directors - Christian Åbyholm</b>   |                    |                  |                    |              |                     |                                       |
| Ordinær   | 130,023,259        | 2,030,221        | 132,053,480        | 0            | 0                   | 132,053,480                           |
| votes cast in %   | 98.46 %            | 1.54 %           | 0.00 %             |              |                     |                                       |
| representation of sc in %   | 98.46 %            | 1.54 %           | 100.00 %           | 0.00 %       | 0.00 %              |                                       |
| total sc in %   | 39.82 %            | 0.62 %           | 40.44 %            | 0.00 %       | 0.00 %              |                                       |
| <b>Total</b>  | <b>130,023,259</b> | <b>2,030,221</b> | <b>132,053,480</b> | <b>0</b>     | <b>0</b>            | <b>132,053,480</b>                    |
| <b>Agenda item 9 Remuneration to the Board of Directors</b>   |                    |                  |                    |              |                     |                                       |
| Ordinær   | 132,042,199        | 5,000            | 132,047,199        | 6,281        | 0                   | 132,053,480                           |
| votes cast in %   | 100.00 %           | 0.00 %           | 0.00 %             |              |                     |                                       |
| representation of sc in %   | 99.99 %            | 0.00 %           | 100.00 %           | 0.01 %       | 0.00 %              |                                       |
| total sc in %   | 40.44 %            | 0.00 %           | 40.44 %            | 0.00 %       | 0.00 %              |                                       |
| <b>Total</b>  | <b>132,042,199</b> | <b>5,000</b>     | <b>132,047,199</b> | <b>6,281</b> | <b>0</b>            | <b>132,053,480</b>                    |
| <b>Agenda item 10 Election of the Nomination Committee</b>  |                    |                  |                    |              |                     |                                       |
| Ordinær   | 132,047,380        | 5,000            | 132,052,380        | 1,100        | 0                   | 132,053,480                           |
| votes cast in %   | 100.00 %           | 0.00 %           | 0.00 %             |              |                     |                                       |
| representation of sc in %   | 100.00 %           | 0.00 %           | 100.00 %           | 0.00 %       | 0.00 %              |                                       |
| total sc in %   | 40.44 %            | 0.00 %           | 40.44 %            | 0.00 %       | 0.00 %              |                                       |
| <b>Total</b>  | <b>132,047,380</b> | <b>5,000</b>     | <b>132,052,380</b> | <b>1,100</b> | <b>0</b>            | <b>132,053,480</b>                    |
| <b>Agenda item 11 Remuneration to the Nomination Committee</b>  |                    |                  |                    |              |                     |                                       |
| Ordinær   | 132,043,299        | 5,000            | 132,048,299        | 5,181        | 0                   | 132,053,480                           |

| Shares class  | For                | Against          | Poll in            | Abstain      | Poll not registered | Represented shares with voting rights |
|---|--------------------|------------------|--------------------|--------------|---------------------|---------------------------------------|
| votes cast in %   | 100.00 %           | 0.00 %           |                    | 0.00 %       |                     |                                       |
| representation of sc in %   | 99.99 %            | 0.00 %           | 100.00 %           | 0.00 %       | 0.00 %              |                                       |
| total sc in %   | 40.44 %            | 0.00 %           | 40.44 %            | 0.00 %       | 0.00 %              |                                       |
| <b>Total</b>  | <b>132,043,299</b> | <b>5,000</b>     | <b>132,048,299</b> | <b>5,181</b> | <b>0</b>            | <b>132,053,480</b>                    |
| <b>Agenda item 12 Board authorisation to issue shares</b>                                       |                    |                  |                    |              |                     |                                       |
| Ordinær   | 125,992,091        | 6,061,389        | 132,053,480        | 0            | 0                   | 132,053,480                           |
| votes cast in %   | 95.41 %            | 4.59 %           |                    | 0.00 %       |                     |                                       |
| representation of sc in %   | 95.41 %            | 4.59 %           | 100.00 %           | 0.00 %       | 0.00 %              |                                       |
| total sc in %   | 38.58 %            | 1.86 %           | 40.44 %            | 0.00 %       | 0.00 %              |                                       |
| <b>Total</b>  | <b>125,992,091</b> | <b>6,061,389</b> | <b>132,053,480</b> | <b>0</b>     | <b>0</b>            | <b>132,053,480</b>                    |
| <b>Agenda item 13 Board authorisation to issue shares in connection with incentive programs</b> |                    |                  |                    |              |                     |                                       |
| Ordinær   | 126,016,858        | 6,036,622        | 132,053,480        | 0            | 0                   | 132,053,480                           |
| votes cast in %   | 95.43 %            | 4.57 %           |                    | 0.00 %       |                     |                                       |
| representation of sc in %   | 95.43 %            | 4.57 %           | 100.00 %           | 0.00 %       | 0.00 %              |                                       |
| total sc in %   | 38.59 %            | 1.85 %           | 40.44 %            | 0.00 %       | 0.00 %              |                                       |
| <b>Total</b>  | <b>126,016,858</b> | <b>6,036,622</b> | <b>132,053,480</b> | <b>0</b>     | <b>0</b>            | <b>132,053,480</b>                    |

Registrar for the company:

Signature company:

NORDEA BANK ABP, FILIAL NORGE

Nykode Therapeutics ASA

#### Share information

| Name        | Total number of shares | Nominal value | Share capital | Voting rights |
|-------------|------------------------|---------------|---------------|---------------|
| Ordinær     | 326,546,444            | 0.01          | 3,265,464.44  | Yes           |
| <b>Sum:</b> |                        |               |               |               |

**§ 5-17 Generally majority requirement**  
requires majority of the given votes

**§ 5-18 Amendment to resolution**

Requires two-thirds majority of the given votes  
like the issued share capital represented/attended on the general meeting